去势抵抗性前列腺癌最新指南解读——暨中国西部专家共识

Assessment of updated guidelines for castration-resistant prostate cancer—Western China expert consensus conference

2016中国西部去势抵抗性前列腺癌专家会议于年初顺利举行。本次会议中,各参会专家就目前去势抵抗性前列腺癌(CRPC)最新诊疗指南进行了解读,同时对CRPC管理中所面临的七大问题进行了激烈讨论。随着六大CRPC治疗药物相继在美国上市及在CRPC基础研究领域所取得的长足进步,不仅给CRPC患者的治疗带来更多选择,同时给医务工作者带了在CRPC管理及治疗过程中的困惑,包括:如何选择最佳治疗药物,最佳的药物序贯治疗方案,预测患者疗效指标及如何评估药物疗效等诸多问题。同时,在我国西部地区,泌尿外科医生亦面临着疾病诊断不足,M1-CRPC(metastatic-CRPC)比重较高,西部地区医疗水平相对落后及患者的经济状况普遍较差等问题。上述问题在CRPC的治疗过程中不仅至关重要且十分棘手。对此,本次会议就上述问题进行了讨论,本文结合参会专家意见及相关指南的推荐共识整理推荐意见如下。

The 2016 Western China Castration-Resistant Prostate Cancer Expert Consensus Conference identified and reviewed the available evidences for the seven most important areas of controversy in castration-resistant prostate cancer（CRPC）management.The successful registration of six drugs for CRPC and great strides made in basic research have led to considerable uncertainty as to the best treatment choices,sequence of treatment options,predictive biomarkers and assessment of therapeutic efficacy.In terms of insufficient diagnosis,high proportion of metastatic-CRPC（M1-CRPC）,relative-low level of healthcare system and economic constraints in Western China,the therapeutic management of CRPC is essential but challenging for urologists in Western region.In this expert panel,the updated guidelines are reviewed and accessed by participating experts,and management recommendations based on expert opinions and available evidences are presented,in order to provide reference for CRPC patients and urologistsin management decisions.